Stereoselective interactions of warfarin enantiomers with the pregnane X nuclear receptor in gene regulation of major drug-metabolizing cytochrome P450 enzymes

Journal of Thrombosis and Haemostasis

Volumn 8, Issue 12, 2010, Pages 2708-2717

  Rulcova, A ^a   Prokopova, I ^a   Krausova, L ^a   Bitman, M ^a   Vrzal, R ^b   Dvorak, Z ^b   Blahos, J ^c   Pavek, P ^a  

^a Charles University in Prague Faculty of Pharmacy   (Czech Republic)

^b PALACKÝ UNIVERSITY   (Czech Republic)

^c INSTITUTE OF MOLECULAR GENETICS   (Czech Republic)

Author keywords

Cytochrome P450; Enantiomers; Gene regulation; PXR; Warfarin

Indexed keywords

CONSTITUTIVE ANDROSTANE RECEPTOR; CYTOCHROME P450 2B6; CYTOCHROME P450 2C9; CYTOCHROME P450 3A4; DRUG METABOLIZING ENZYME; GLUCOCORTICOID RECEPTOR; GLYCOPROTEIN P; MESSENGER RNA; PREGNANE X RECEPTOR; VITAMIN D RECEPTOR; WARFARIN;

ARTICLE; DRUG POTENCY; DRUG RECEPTOR BINDING; ENANTIOMER; ENZYME INDUCTION; FLUORESCENCE RESONANCE ENERGY TRANSFER; GENE CONTROL; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; PRIORITY JOURNAL; RECEPTOR UPREGULATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STEREOCHEMISTRY;

ANTICOAGULANTS; CELL LINE, TUMOR; CYTOCHROME P-450 ENZYME SYSTEM; FLUORESCENCE RESONANCE ENERGY TRANSFER; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENES, REPORTER; HUMANS; RECEPTORS, STEROID; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; STEREOISOMERISM; TRANSCRIPTIONAL ACTIVATION; TWO-HYBRID SYSTEM TECHNIQUES; UP-REGULATION; WARFARIN;

EID: 78649986387     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2010.04036.x     Document Type: Article

References (41)

1. Shapiro S. Warfarin sodium derivative: (coumadin sodium); an intravenous hypoprothrombinemia-inducing agent. Angiology 1953; 4: 380-90.
2. Wolff JM, Barker NW, Gifford RW, Mann FD. Experience with a new intravenous coumarin anticoagulant (warfarin, sodium derivative). Proc Staff Meet Mayo Clin 1953; 28: 489-97.
3. Ansell J, Hirsh J, Poller L, Bussey H, Jacobson A, Hylek E. The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126: 204S-33S.
4. Bell RG, Matschiner JT. Warfarin and the inhibition of vitamin K activity by an oxide metabolite. Nature 1972; 237: 32-3.
5. Rost S, Fregin A, Ivaskevicius V, Conzelmann E, Hortnagel K, Pelz HJ, Lappegard K, Seifried E, Scharrer I, Tuddenham EG, Muller CR, Strom TM, Oldenburg J. Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2. Nature 2004; 427: 537-41.
6. Whitlon DS, Sadowski JA, Suttie JW. Mechanism of coumarin action: significance of vitamin K epoxide reductase inhibition. Biochemistry 1978; 17: 1371-7.
7. Berkner KL, Runge KW. The physiology of vitamin K nutriture and vitamin K-dependent protein function in atherosclerosis. J Thromb Haemost 2004; 2: 2118-32.
8. Shearer MJ, Newman P. Metabolism and cell biology of vitamin K. Thromb Haemost 2008; 100: 530-47.
9. Hewick DS, McEwen J. Plasma half-lives, plasma metabolites and anticoagulant efficacies of the enantiomers of warfarin in man. J Pharm Pharmacol 1973; 25: 458-65.
10. Kaminsky LS, Zhang ZY. Human P450 metabolism of warfarin. Pharmacol Ther 1997; 73: 67-74.
11. Rettie AE, Eddy AC, Heimark LD, Gibaldi M, Trager WF. Characteristics of warfarin hydroxylation catalyzed by human liver microsomes. Drug Metab Dispos 1989; 17: 265-70.
12. Miller GP, Jones DR, Sullivan SZ, Mazur A, Owen SN, Mitchell NC, Radominska-Pandya A, Moran JH. Assessing cytochrome P450 and UDP-glucuronosyltransferase contributions to warfarin metabolism in humans. Chem Res Toxicol 2009; 22: 1239-45.
13. Rettie AE, Korzekwa KR, Kunze KL, Lawrence RF, Eddy AC, Aoyama T, Gelboin HV, Gonzalez FJ, Trager WF. Hydroxylation of warfarin by human cDNA-expressed cytochrome P-450: a role for P-4502C9 in the etiology of (S)-warfarin-drug interactions. Chem Res Toxicol 1992; 5: 54-9.
14. Gebauer M. Synthesis and structure-activity relationships of novel warfarin derivatives. Bioorg Med Chem 2007; 15: 2414-20.
15. Obaseki AO, Coker HB. The anticoagulant activity of some selected warfarin analogues. J Pharm Pharmacol 1987; 39: 142-4.
16. Zhang Z, Fasco MJ, Huang Z, Guengerich FP, Kaminsky LS. Human cytochromes P4501A1 and P4501A2: R-warfarin metabolism as a probe. Drug Metab Dispos 1995; 23: 1339-46.
17. Hermans JJ, Thijssen HH. The in vitro ketone reduction of warfarin and analogues. Substrate stereoselectivity, product stereoselectivity and species differences. Biochem Pharmacol 1989; 38: 3365-70.
18. Jansing RL, Chao ES, Kaminsky LS. Phase II metabolism of warfarin in primary culture of adult rat hepatocytes. Mol Pharmacol 1992; 41: 209-15.
19. Pavek P, Dvorak Z. Xenobiotic-induced transcriptional regulation of xenobiotic metabolizing enzymes of the cytochrome P450 superfamily in human extrahepatic tissues. Curr Drug Metab 2008; 9: 129-43.
20. Zhou C, Verma S, Blumberg B. The steroid and xenobiotic receptor (SXR), beyond xenobiotic metabolism. Nucl Recept Signal 2009; 7: e001.
21. Martinez-Jimenez CP, Jover R, Donato MT, Castell JV, Gomez-Lechon MJ. Transcriptional regulation and expression of CYP3A4 in hepatocytes. Curr Drug Metab 2007; 8: 185-94.
22. Tirona RG, Kim RB. Nuclear receptors and drug disposition gene regulation. J Pharm Sci 2005; 94: 1169-86.
23. Orans J, Teotico DG, Redinbo MR. The nuclear xenobiotic receptor pregnane X receptor: recent insights and new challenges. Mol Endocrinol 2005; 19: 2891-900.
24. Tabb MM, Sun A, Zhou C, Grun F, Errandi J, Romero K, Pham H, Inoue S, Mallick S, Lin M, Forman BM, Blumberg B. Vitamin K2 regulation of bone homeostasis is mediated by the steroid and xenobiotic receptor SXR. J Biol Chem 2003; 278: 43919-27.
25. Igarashi M, Yogiashi Y, Mihara M, Takada I, Kitagawa H, Kato S. Vitamin K induces osteoblast differentiation through pregnane X receptor-mediated transcriptional control of the Msx2 gene. Mol Cell Biol 2007; 27: 7947-54.
26. Ichikawa T, Horie-Inoue K, Ikeda K, Blumberg B, Inoue S. Steroid and xenobiotic receptor SXR mediates vitamin K2-activated transcription of extracellular matrix-related genes and collagen accumulation in osteoblastic cells. J Biol Chem 2006; 281: 16927-34.
27. Zhou SF. Drugs behave as substrates, inhibitors and inducers of human cytochrome P450 3A4. Curr Drug Metab 2008; 9: 310-22.
28. Cerveny L, Svecova L, Anzenbacherova E, Vrzal R, Staud F, Dvorak Z, Ulrichova J, Anzenbacher P, Pavek P. Valproic acid induces CYP3A4 and MDR1 gene expression by activation of constitutive androstane receptor and pregnane X receptor pathways. Drug Metab Dispos 2007; 35: 1032-41.
29. Pavek P, Pospechova K, Svecova L, Syrova Z, Stejskalova L, Blazkova J, Dvorak Z, Blahos J. Intestinal cell-specific vitamin D receptor (VDR)-mediated transcriptional regulation of CYP3A4 gene. Biochem Pharmacol 2010; 79: 277-87.
30. Svecova L, Vrzal R, Burysek L, Anzenbacherova E, Cerveny L, Grim J, Trejtnar F, Kunes J, Pour M, Staud F, Anzenbacher P, Dvorak Z, Pavek P. Azole antimycotics differentially affect rifampicin-induced pregnane X receptor-mediated CYP3A4 gene expression. Drug Metab Dispos 2008; 36: 339-48.
31. Wang H, Li H, Moore LB, Johnson MD, Maglich JM, Goodwin B, Ittoop OR, Wisely B, Creech K, Parks DJ, Collins JL, Willson TM, Kalpana GV, Venkatesh M, Xie W, Cho SY, Roboz J, Redinbo M, Moore JT, Mani S. The phytoestrogen coumestrol is a naturally occurring antagonist of the human pregnane X receptor. Mol Endocrinol 2008; 22: 838-57.
32. Rodriguez-Antona C, Donato MT, Pareja E, Gomez-Lechon MJ, Castell JV. Cytochrome P-450 mRNA expression in human liver and its relationship with enzyme activity. Arch Biochem Biophys 2001; 393: 308-15.
33. Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 2001; 29: e45.
34. Malakova J, Pavek P, Svecova L, Jokesova I, Zivny P, Palicka V. New high-performance liquid chromatography method for the determination of (R)-warfarin and (S)-warfarin using chiral separation on a glycopeptide-based stationary phase. J Chromatogr B Analyt Technol Biomed Life Sci 2009; 877: 3226-30.
35. Jones DR, Kim SY, Guderyon M, Yun CH, Moran JH, Miller GP. Hydroxywarfarin metabolites potently inhibit CYP2C9 Metabolism of S-Warfarin. Chem Res Toxicol 2010; 23: 939-45.
36. Locatelli I, Kmetec V, Mrhar A, Grabnar I. Determination of warfarin enantiomers and hydroxylated metabolites in human blood plasma by liquid chromatography with achiral and chiral separation. J Chromatogr B Analyt Technol Biomed Life Sci 2005; 818: 191-8.
37. Pal D, Mitra AK. MDR- and CYP3A4-mediated drug-drug interactions. J Neuroimmune Pharmacol 2006; 1: 323-39.
38. Jones DR, Kim SY, Boysen G, Yun CH, Miller GP. Contribution of three CYP3A isoforms to metabolism of R- and S-warfarin. Drug Metab Lett 2010; in press.
39. McAleer SD, Foondun AS, Feely M, Chrystyn H. Steady-state clearance rates of warfarin and its enantiomers in therapeutically dosed patients. Chirality 1997; 9: 13-6.
40. Kwan KC. Oral bioavailability and first-pass effects. Drug Metab Dispos 1997; 25: 1329-36.
41. Pifferi G, Perucca E. The cost benefit ratio of enantiomeric drugs. Eur J Drug Metab Pharmacokinet 1995; 20: 15-25.